Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06389799 |
| Title | A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) (PERELI) |
| Acronym | PERELI |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Lund University Hospital |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | SWE | NOR |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Oslo University Hospital HF | NOT_YET_RECRUITING | Oslo | Norway | Details | ||
| Sahlgrenska University Hospital | RECRUITING | Göteborg | Sweden | Details | ||
| Skåne University Hospital | RECRUITING | Lund | Sweden | Details |